# Effect of Sodium NItroprusside (SNP) on R,S- and S-Ketamine-induced psychotropic side effects, hemodynamic changes and pain relief in healthy volunteers

Published: 04-03-2015 Last updated: 14-04-2024

The objectives of the study are to assess whether:(1) SNP will reduce the occurrence of psychomimetic side effects during exposure to low-dose ketamine;(2) SNP will reduce the ketamine-induced increase in blood pressure and cardiac output;(3) SNP is...

**Ethical review** Approved WMO

**Status** Recruitment stopped

**Health condition type** Other condition

**Study type** Observational invasive

## Summary

#### ID

NL-OMON43889

Source

**ToetsingOnline** 

**Brief title** 

**SNIK** 

#### Condition

Other condition

### **Synonym**

Chronic Pain, neuropathic pain

#### **Health condition**

chronische (neuropathische) pijn

## Research involving

Human

## **Sponsors and support**

Primary sponsor: Leids Universitair Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

#### Intervention

**Keyword:** Ketamine, Pain relief, Side effects

## **Outcome measures**

### **Primary outcome**

Psychedelic and negative effects are measured using visual analog scales

ranging from 0 (no effect) to 10 cm (maximum effect) of the Bowdle and Bond &

Lader questionnaires (Appendix 1A and B).11,12

## **Secondary outcome**

Pain relief from ketamine (S vs RS) and placebo vs SNP.

# **Study description**

### **Background summary**

Since its introduction in the early 1960s in clinical practice, ketamine has progressed from a general anesthetic to a more versatile drug and is currently frequently used in the treatment of acute and chronic pain, therapy-resistant major depression, migraine and post-traumatic stress disorder. Ketamine is a drug that interacts with many receptors but antagonism of the N-methyl-D-aspartate receptor (NMDAR), an excitatory glutamate receptor ubiquitously present in the central nervous system, is considered most important. An important negative ketamine effect, that causes many physicians to be cautious with its use, is the induction of dissociative, psychomimetic and other central nervous system (CNS)-related side effects. We hypothesize that negative effects during ketamine treatment is related to the reduced NO formation from NMDAR antagonism. In this study we will assess the effect of sodium nitroprusside (SNP), and NO donor, on ketamine\*s positive and negative effects in a group of healthy volunteers. The effect of SNP will be tested in

subjects that received the S-enantiomer S-ketamine or racemic (R,S) ketamine.

## Study objective

The objectives of the study are to assess whether:

- (1) SNP will reduce the occurrence of psychomimetic side effects during exposure to low-dose ketamine;
- (2) SNP will reduce the ketamine-induced increase in blood pressure and cardiac output;
- (3) SNP is without effect on ketamine-induced pain relief;
- (4) SNP is effective in reducing negative effects in both S-ketamine and RS-ketamine treated subjects.

## Study design

Double blind, randomized and placebo controlled

## Study burden and risks

The expected side effects are topic of the study. We expect mild effects with most prevalent symptoms \*drug high\* and dizziness. Other side effects that may occur are nausea (which we will treat with ondansetron 4 mg iv), hypertension (we expect just mild effects with an increase in CO from 6 to about 9 L/min; this is an acceptable and mild increase), mild tachycardia. During concomitant infusion of SNP the hemodynamics effects will possibly be less. Finally some bruising and hematomas formation may occur at sites at which the iv and arterial entered the skin. The pain tests cause no side effects.

## **Contacts**

#### **Public**

Leids Universitair Medisch Centrum

Albinusdreef 2 Leiden 2333 ZA NL

#### Scientific

Leids Universitair Medisch Centrum

Albinusdreef 2 Leiden 2333 ZA NL

## **Trial sites**

## **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

## Age

Adults (18-64 years) Elderly (65 years and older)

## Inclusion criteria

Male subjects, aged 18-34 years with a body mass index < 30 kg/m2.

## **Exclusion criteria**

Severe medical disease including hypertension, liver/renal disease, neurological disorders, diaphragmatic hernia/pyrosis; (history of) psychiatric or neurological disease; allergy to study medication; (history of) illicit drug abuse/alcoholism.

# Study design

## **Design**

Study type: Observational invasive

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Placebo

Primary purpose: Prevention

## Recruitment

NL

4 - Effect of Sodium NItroprusside (SNP) on R,S- and S-Ketamine-induced psychotropic ... 13-05-2025

Recruitment status: Recruitment stopped

Start date (anticipated): 20-04-2015

Enrollment: 26

Type: Actual

## Medical products/devices used

Product type: Medicine

Brand name: Ketalar

Generic name: RS-ketamine

Registration: Yes - NL intended use

Product type: Medicine

Brand name: Ketanest

Generic name: S(+)-ketamine

Product type: Medicine

Brand name: Sodium Nitroprusside

Generic name: Sodium Nitroprusside

Registration: Yes - NL outside intended use

## **Ethics review**

Approved WMO

Date: 04-03-2015

Application type: First submission

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

Approved WMO

Date: 01-04-2015

Application type: First submission

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

Approved WMO

Date: 17-07-2015

Application type: Amendment

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

Approved WMO

Date: 11-08-2015

Application type: Amendment

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

Approved WMO

Date: 25-11-2015

Application type: Amendment

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

Approved WMO

Date: 09-06-2016
Application type: Amendment

Review commission: METC Leids Universitair Medisch Centrum (Leiden)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

EudraCT EUCTR2015-000550-37-NL

CCMO NL52444.058.15

# **Study results**

Date completed: 24-08-2017

Actual enrolment: 36

#### **Summary results**

Trial is onging in other countries